- Home
- TRX vs ADAG Comparison
TRX vs ADAG Comparison
Compare TRX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- ADAG
- Stock Information
- Founded
- TRX 1990
- ADAG 2011
- Country
- TRX Canada
- ADAG China
- Employees
- TRX N/A
- ADAG N/A
- Industry
- TRX
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- TRX
- ADAG Health Care
- Exchange
- TRX Nasdaq
- ADAG Nasdaq
- Market Cap
- TRX 95.9M
- ADAG 110.8M
- IPO Year
- TRX N/A
- ADAG 2021
- Fundamental
- Price
- TRX $0.52
- ADAG $2.04
- Analyst Decision
- TRX Strong Buy
- ADAG Strong Buy
- Analyst Count
- TRX 1
- ADAG 2
- Target Price
- TRX $1.10
- ADAG $7.00
- AVG Volume (30 Days)
- TRX 1.3M
- ADAG 111.6K
- Earning Date
- TRX 07-15-2025
- ADAG 08-12-2025
- Dividend Yield
- TRX N/A
- ADAG N/A
- EPS Growth
- TRX N/A
- ADAG N/A
- EPS
- TRX N/A
- ADAG N/A
- Revenue
- TRX $47,731,000.00
- ADAG $103,204.00
- Revenue This Year
- TRX $23.64
- ADAG $9,789.15
- Revenue Next Year
- TRX $51.77
- ADAG $29.92
- P/E Ratio
- TRX $498.50
- ADAG N/A
- Revenue Growth
- TRX 29.98
- ADAG N/A
- 52 Week Low
- TRX $0.27
- ADAG $1.33
- 52 Week High
- TRX $0.55
- ADAG $3.16
- Technical
- Relative Strength Index (RSI)
- TRX 80.75
- ADAG 45.09
- Support Level
- TRX $0.51
- ADAG $2.24
- Resistance Level
- TRX $0.55
- ADAG $2.49
- Average True Range (ATR)
- TRX 0.03
- ADAG 0.22
- MACD
- TRX 0.01
- ADAG -0.03
- Stochastic Oscillator
- TRX 84.35
- ADAG 0.44
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.